Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years on the day of signing informed consent.~2. Histologically confirmed diagnosis of cHL.~3. Disease status as defined as.~   * Refractory patients who are naïve to anti-PD-1/PDL-1 therapy OR Relapsed after 3 or more lines of therapies; and are naïve to anti-PD-1/PDL-1 therapy OR~  * Patients currently on Pembrolizumab and achieve a less than complete response~4. Must have ECOG performance status of 0 or 1~5. At least one bi-dimensional measurable lesion with minimum measurement of \> 15 mm in the longest diameter.~6. Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia.~   1. Adequate bone marrows, liver and renal function as assessed by the following laboratory requirements. Hemoglobin ≥8.0 g/dL (may not be transfused or treated with erythropoietin in preceding week to maintain or exceed this level)~  2. Absolute neutrophil count (ANC) ≥1,000/µL~  3. Platelet count ≥75,000/μL~  4. Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)~  5. ALT and AST ≤2.5 x ULN~  6. Serum creatinine ≤ 1.5 x ULN or CrCl \> 60 ml/min (Cockcroft-Gault formula)~7. Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential~8. Provide written informed consent prior to any study-specific screening procedures.~9. Willingness and capability to comply with the requirements of the study.~Exclusion Criteria:~1. Patient receiving anticancer therapy (e.g. chemotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) ≤3 weeks or 5 half-lives (whichever is shorter) prior to C1D1,~2. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)~3. Radiotherapy within the last 21 days prior to C1D1 (limited field palliative radiation is allowed if ≥ 14 days prior to C1D1);~4. Investigational drug therapy outside of this trial during or within 3 weeks prior to C1D1.~5. Patients with Allo-SCT on active GVHD or immunosuppression therapy within 3 months prior to C1D1.~6. Patient with active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications .~7. Pregnancy or lactation.~8. Known clinically active CNS involvement.~9. Evidence of active Hepatitis B, active Hepatitis C infection (HCV) or cytomegalovirus (CMV) or known history of HIV.~10. Subjects with concomitant second malignancies~11. Patient with any active immune toxicity of Grade 1 or greater or any other severe or Grade 3 treatment-related adverse event.~12. History of Grade 4 anaphylactic reaction to monoclonal antibody therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenalisib+Pembrolizumab (Type: EXPERIMENTAL): Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.

Based on this trial design, predict the completion outcome and termination type (if applicable).